clinical trial · NCT05642429
Study of AV-1959D, an Amyloid Beta Vaccine
Institute for Molecular Medicine·phase1·active not recruiting·n = 48
Alzheimer DiseaseAV-1959DPlacebo
brief summary
Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
started
Feb 27, 2023
primary completion
Jul 20, 2026
completion
Nov 7, 2026
last updated
Mar 27, 2026
detailed description
The Phase I study is a randomized, multicenter, double-blind, placebo-controlled study consisting of 3 sequential cohorts to determine the safety and tolerability of AV-1959D at three doses compared to a placebo in patients with early AD
official title
A Phase I, Randomized, Double-Blind Study to Evaluate Safety and Tolerability of Amyloid-β Vaccine, AV-1959D, in Patients With Early Alzheimer's Disease.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol